JB Chemicals gets USFDA nod for hypertension drug Bisoprolol
Mumbai: J.B. Chemicals & Pharmaceuticals Limited has announced that the company has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA), Bisoprolol Tablets USP, 5 mg, and 10 mg.
The product is the generic version of Zebeta (Teva).
Bisoprolol Tablets are indicated in the management of hypertension.
Hypertension is a condition where the force of the blood against the artery walls is consistently too high. It's often called a "silent killer" because it usually has no symptoms but can lead to serious health issues.
Read also: JB Chemicals and Pharma Panoli facility concludes USFDA inspection no observations
Established in 1976, J.B. Pharma is a pharmaceutical company headquartered in Mumbai, India. Besides India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it also manufactures medicated lozenges. It has eight state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.
Read also: KKR divests 5.8 percent stake in JB Chemicals & Pharma for Rs 1460 crore
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.